Prospective, multicentre, single-arm phase II trial of pembrolizumab combined with carboplatin and pemetrexed in elderly patients with advanced, non-squamous non-small cell lung cancer

被引:0
作者
Ozawa, Yuichi [1 ]
Sugimoto, Takeya [1 ]
Azuma, Yuichiro [2 ]
Harutani, Yuhei [3 ]
Yoshikawa, Takanori [4 ]
Yamamoto, Nobuyuki [1 ]
Kanai, Kuninobu [5 ]
机构
[1] Wakayama Med Univ, Internal Med 3, Wakayama, Japan
[2] Natl Hosp Org, Dept Resp Med, Wakayama Hosp, Mihama, Japan
[3] Natl Hosp Org, Dept Resp Med, Minami Wakayama Med Ctr, Tanabe, Japan
[4] Wakayama Med Univ, Clin Study Support Ctr, Wakayama, Japan
[5] Naga Municipal Hosp, Dept Resp Med, Kinokawa, Japan
关键词
chemotherapy; oncology; clinical trials; CHEMOTHERAPY; MONOTHERAPY;
D O I
10.1136/bmjopen-2020-037746
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction Triplet regimen of carboplatin or cisplatin with pemetrexed and pembrolizumab is a standard treatment for patients with advanced, chemo-naive, non-squamous non-small cell lung cancer. However, subgroup analysis for patients aged >= 75 years indicated that elderly patients who received the triplet regimen may have had shorter survival times than if they had chemotherapy alone (HR of 2.09). Treatments in the elderly are not always as effective or safe as for non-elderly patients, so there remains concern over whether the triplet regimen can be widely used in the elderly. Methods and analysis This is a single-arm, prospective, multicentre phase II study. The primary endpoint is set as the overall response rate according toResponse Evaluation Criteria in Solid TumorsV.1.1. Secondary endpoints are progression-free survival, disease control rate and safety. This trial will enrol 22 patients. Ethics and dissemination This study was approved by the Wakayama Medical University Central Review Board on 2 December 2019 (approval number: W-32). Patients have been enrolled since February 2020. As the study will complete accrual in January 2022, results will be submitted for publication in peer-reviewed medical journals within 2023 and international scientific meetings. This study will provide significant information on whether the triplet regimens are clinically beneficial to elderly patients.
引用
收藏
页数:7
相关论文
共 6 条
[1]   Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer [J].
Gandhi, L. ;
Rodriguez-Abreu, D. ;
Gadgeel, S. ;
Esteban, E. ;
Felip, E. ;
De Angelis, F. ;
Domine, M. ;
Clingan, P. ;
Hochmair, M. J. ;
Powell, S. F. ;
Cheng, S. Y. -S. ;
Bischoff, H. G. ;
Peled, N. ;
Grossi, F. ;
Jennens, R. R. ;
Reck, M. ;
Hui, R. ;
Garon, E. B. ;
Boyer, M. ;
Rubio-Viqueira, B. ;
Novello, S. ;
Kurata, T. ;
Gray, J. E. ;
Vida, J. ;
Wei, Z. ;
Yang, J. ;
Raftopoulos, H. ;
Pietanza, M. C. ;
Garassino, M. C. .
NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (22) :2078-2092
[2]   Pemetrexed and carboplatin, an active option in first-line treatment of elderly patients with advanced non-small cell lung cancer (NSCLC): A phase II trial [J].
Gervais, Radj ;
Robinet, Gilles ;
Clement-Duchene, Christelle ;
Denis, Fabrice ;
El Kouri, Claude ;
Martin, Philippe ;
Chouaki, Nadia ;
Bourayou, Nawel ;
Morere, Jean-Francois .
LUNG CANCER, 2013, 80 (02) :185-190
[3]   Chemotherapy for elderly patients with advanced non-small-cell lung cancer:: The Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial [J].
Gridelli, C ;
Perrone, F ;
Gallo, C ;
Cigolari, S ;
Rossi, A ;
Piantedosi, F ;
Barbera, S ;
Ferraù, F ;
Piazza, E ;
Rosetti, F ;
Clerici, M ;
Bertetto, O ;
Robbiati, SF ;
Frontini, L ;
Sacco, C ;
Castiglione, F ;
Favaretto, A ;
Novello, S ;
Migliorino, MR ;
Gasparini, G ;
Galetta, D ;
Iaffaioli, RV ;
Gebbia, V .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003, 95 (05) :362-372
[4]   Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1 positive advanced non small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies [J].
Nosaki, Kaname ;
Saka, Hideo ;
Hosomi, Yukio ;
Baas, Paul ;
de Castro, Gilberto, Jr. ;
Reck, Martin ;
Wu, Yi-Long ;
Brahmer, Julie R. ;
Felip, Enriqueta ;
Sawada, Takeshi ;
Noguchi, Kazuo ;
Han, Shi Rong ;
Piperdi, Bilal ;
Kush, Debra A. ;
Lopes, Gilberto .
LUNG CANCER, 2019, 135 :188-195
[5]  
Okamoto I, 2019, J CLIN ONCOL, V37
[6]   Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial [J].
Quoix, Elisabeth ;
Zalcman, Gerard ;
Oster, Jean-Philippe ;
Westeel, Virginie ;
Pichon, Eric ;
Lavole, Armelle ;
Dauba, Jerome ;
Debieuvre, Didier ;
Souquet, Pierre-Jean ;
Bigay-Game, Laurence ;
Dansin, Eric ;
Poudenx, Michel ;
Molinier, Olivier ;
Vaylet, Fabien ;
Moro-Sibilot, Denis ;
Herman, Dominique ;
Bennouna, Jaafar ;
Tredaniel, Jean ;
Ducolone, Alain ;
Lebitasy, Marie-Paule ;
Baudrin, Laurence ;
Laporte, Silvy ;
Milleron, Bernard .
LANCET, 2011, 378 (9796) :1079-1088